Clinical efficacy and safety of first-line treatments in patients with mantle cell lymphoma: A systematic literature review
Neerav Monga, Christoph Tapprich(Janssen (Germany)), Constantine S. Tam(The Alfred Hospital), Joan Quigley(Imperial Consultants), Matthew S. Davids(Dana-Farber Cancer Institute), Lori Parisi(Janssen (United States)), Jamie Garside(Janssen (United Kingdom)), Katherine N. Ward(Hammersmith Hospital)
Cited by 12
Related Papers
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
|Journal of Clinical Oncology|2017|752